ESBL and MBL in Cefepime Resistant Pseudomonas aeruginosa : An Update from a Rural Area in Northern India | Zendy

Aarti Kotwal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

ESBL and MBL in Cefepime Resistant Pseudomonas aeruginosa : An Update from a Rural Area in Northern India

Author(s) -

Aarti Kotwal

Publication year - 2016

Publication title -

journal of clinical and diagnostic research

Language(s) - English

Resource type - Journals

eISSN - 2249-782X

pISSN - 0973-709X

DOI - 10.7860/jcdr/2016/18016.7612

Subject(s) - cefepime , cefoperazone , amikacin , piperacillin , pseudomonas aeruginosa , medicine , microbiology and biotechnology , imipenem , ceftazidime , cephalosporin , ciprofloxacin , tazobactam , sulbactam , antibiotics , antibiotic resistance , biology , bacteria , genetics

Cefepime, a fourth generation cephalosporin, is widely used for the empirical treatment of serious infections in critically ill hospitalized patients. Pseudomonas aeruginosa (P. aeruginosa), one of the commonest bacteria causing nosocomial infections has a propensity to develop antibiotic resistance quite promptly.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research